Kala Pharmaceuticals, Inc. – NASDAQ:KALA
Kala Pharmaceuticals stock price today
$8.57
+1.58
+22.78%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 11 hours
Kala Pharmaceuticals stock price monthly change
-6.68%
month
Kala Pharmaceuticals stock price quarterly change
-6.68%
quarter
Kala Pharmaceuticals stock price yearly change
-9.35%
year
Kala Pharmaceuticals key metrics
Market Cap | 27.15M |
Enterprise value | N/A |
P/E | -0.61 |
EV/Sales | -0.02 |
EV/EBITDA | N/A |
Price/Sales | 7.05 |
Price/Book | 1.44 |
PEG ratio | N/A |
EPS | -15.15 |
Revenue | N/A |
EBITDA | -38.30M |
Income | -39.55M |
Revenue Q/Q | N/A |
Revenue Y/Y | -98.13% |
Profit margin | -1151.64% |
Oper. margin | -2090.34% |
Gross margin | 34.22% |
EBIT margin | -2090.34% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeKala Pharmaceuticals stock price history
Kala Pharmaceuticals stock forecast
Kala Pharmaceuticals financial statements
| Jun 2023 | 0 | -10.41M | |
|---|---|---|---|
| Sep 2023 | 0 | -8.70M | |
| Dec 2023 | 70K | -8.62M | -12324.29% |
| Mar 2024 | 0 | -11.80M |
| Dec 2023 | 70K | -8.62M | -12324.29% |
|---|---|---|---|
| Mar 2024 | 0 | -11.80M | |
| Oct 2025 | 0 | -4.58M | |
| Dec 2025 | 0 | -4.55M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 66500000 | 49.00M | 73.7% |
|---|---|---|---|
| Sep 2023 | 61120000 | 49.89M | 81.64% |
| Dec 2023 | 55949000 | 48.44M | 86.59% |
| Mar 2024 | 53033000 | 46.37M | 87.44% |
| Jun 2023 | -7.59M | -10.03M | 3.07M |
|---|---|---|---|
| Sep 2023 | -2.95M | 9.71M | 40K |
| Dec 2023 | -7.69M | -7K | 2.53M |
| Mar 2024 | -10.84M | -13K | 8.44M |
Kala Pharmaceuticals alternative data
| Aug 2023 | 34 |
|---|---|
| Sep 2023 | 34 |
| Oct 2023 | 34 |
| Nov 2023 | 34 |
| Dec 2023 | 34 |
| Jan 2024 | 34 |
| Feb 2024 | 34 |
| Mar 2024 | 34 |
| Apr 2024 | 34 |
| May 2024 | 43 |
| Jun 2024 | 43 |
| Jul 2024 | 43 |
Kala Pharmaceuticals other data
7.86%
-2.40%
of KALA is owned by hedge funds
44
-16
115.84K
-35.30K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 11400 |
| May 2024 | 0 | 13504 |
| Jun 2024 | 0 | 34631 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | BAZEMORE TODD officer: SEE REMA.. | Common Stock | 4,653 | $4.75 | $22,102 | ||
Sale | BAZEMORE TODD officer: SEE REMA.. | Common Stock | 4,653 | $4.75 | $22,102 | ||
Sale | KHARABI DARIUS officer: CHIEF BUSINESS OFFICER | Common Stock | 5,158 | $4.75 | $24,501 | ||
Sale | REUMUTH MARY officer: CHIEF FINANCIAL OFFICER | Common Stock | 4,163 | $4.75 | $19,774 | ||
Sale | IWICKI MARK T director, officer.. | Common Stock | 15,168 | $4.75 | $72,048 | ||
Sale | IWICKI MARK T director, officer.. | Common Stock | 15,168 | $4.75 | $72,048 | ||
Sale | BRAZZELL ROMULUS K officer: SEE REMARKS | Common Stock | 5,489 | $4.75 | $26,073 | ||
Sale | BAZEMORE TODD officer: SEE REMA.. | Common Stock | 2,093 | $6.09 | $12,746 | ||
Sale | BAZEMORE TODD officer: SEE REMA.. | Common Stock | 2,093 | $6.09 | $12,746 | ||
Sale | KHARABI DARIUS officer: CHIEF BUSINESS OFFICER | Common Stock | 231 | $6.09 | $1,407 |
| Patent |
|---|
Grant Filling date: 19 Oct 2018 Issue date: 2 Aug 2022 |
Application COMPOSITIONS AND METHODS UTILIZING POLY(VINYL ALCOHOL) AND/OR OTHER POLYMERS THAT AID PARTICLE TRANSPORT IN MUCUS Filling date: 30 Mar 2022 Issue date: 14 Jul 2022 |
Grant Filling date: 29 Jun 2020 Issue date: 28 Jun 2022 |
Grant Utility: Urea derivatives and uses thereof Filling date: 12 Jun 2020 Issue date: 7 Jun 2022 |
Grant Utility: Compositions and methods utilizing poly(vinyl alcohol) and/or other polymers that aid particle transport in mucus Filling date: 26 May 2020 Issue date: 3 May 2022 |
Application Filling date: 17 Dec 2021 Issue date: 7 Apr 2022 |
Application Filling date: 19 Feb 2021 Issue date: 23 Dec 2021 |
Application Filling date: 2 Feb 2021 Issue date: 9 Dec 2021 |
Application Filling date: 29 Jul 2021 Issue date: 18 Nov 2021 |
Application Filling date: 10 Mar 2021 Issue date: 18 Nov 2021 |
| Quarter | Transcript |
|---|---|
| Q2 2022 12 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 16 May 2022 | Q1 2022 Earnings Call Transcript |
| Q4 2021 29 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Q3 2021 15 Nov 2021 | Q3 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Mark T. Iwicki (1966) Chairman & Chief Executive Officer | $1,270,000 |
Dr. Kim Brazzell Ph.D. (1953) Head of R&D and Chief Medical Officer | $848,270 |
| Mr. Todd Bazemore (1970) Pres & Chief Operating Officer | $739,540 |
-
What's the price of Kala Pharmaceuticals stock today?
One share of Kala Pharmaceuticals stock can currently be purchased for approximately $8.57.
-
When is Kala Pharmaceuticals's next earnings date?
Unfortunately, Kala Pharmaceuticals's (KALA) next earnings date is currently unknown.
-
Does Kala Pharmaceuticals pay dividends?
No, Kala Pharmaceuticals does not pay dividends.
-
How much money does Kala Pharmaceuticals make?
Kala Pharmaceuticals has a market capitalization of 27.15M.
-
What is Kala Pharmaceuticals's stock symbol?
Kala Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "KALA".
-
What is Kala Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Kala Pharmaceuticals?
Shares of Kala Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Kala Pharmaceuticals's key executives?
Kala Pharmaceuticals's management team includes the following people:
- Mr. Mark T. Iwicki Chairman & Chief Executive Officer(age: 59, pay: $1,270,000)
- Dr. Kim Brazzell Ph.D. Head of R&D and Chief Medical Officer(age: 72, pay: $848,270)
- Mr. Todd Bazemore Pres & Chief Operating Officer(age: 55, pay: $739,540)
-
How many employees does Kala Pharmaceuticals have?
As Jul 2024, Kala Pharmaceuticals employs 43 workers, which is 26% more then previous quarter.
-
When Kala Pharmaceuticals went public?
Kala Pharmaceuticals, Inc. is publicly traded company for more then 8 years since IPO on 20 Jul 2017.
-
What is Kala Pharmaceuticals's official website?
The official website for Kala Pharmaceuticals is kalarx.com.
-
Where are Kala Pharmaceuticals's headquarters?
Kala Pharmaceuticals is headquartered at 1167 Massachusetts Avenue, Arlington, MA.
-
How can i contact Kala Pharmaceuticals?
Kala Pharmaceuticals's mailing address is 1167 Massachusetts Avenue, Arlington, MA and company can be reached via phone at +7 819965252.
Kala Pharmaceuticals company profile:
Kala Pharmaceuticals, Inc.
kalarx.comExchange:
NASDAQ
Full time employees:
43
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.
1167 Massachusetts Avenue
Arlington, MA 02476
Arlington, MA 02476
CIK: 0001479419
ISIN: US4831192020
CUSIP: 483119103
